Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.
(Bloomberg) -- The peptide boom has all the markings of a mainstream wellness craze: podcast evangelists, celebrity converts and a billion-dollar market promising shortcuts to weight loss, muscle gain and a longer life. One major hurdle: actually buying them.Most Read from BloombergUS Strikes Iran in Escalating Campaign After Troops KilledThousands of Trucks Haul Iraq’s Oil Through Syria in Sign of Hormuz LegacyUS Strikes Iran to ‘Punish’ It for Attack That Killed 2 TroopsTrump Silent So Far on
ARKG sold 1.12 million ATAI shares last week but still held 3.19 million shares as of Friday.
Investors rotated into biotech, cybersecurity and insurance stocks with stronger growth prospects and earnings strength.
Maybe you should, too.
All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very different stories about where each stock goes from here.
Eli Lilly stock has delivered a 406.3% return over the past five years, yet its latest valuation checks point to an unusual tension as the Discounted Cash Flow (DCF) intrinsic value suggests the shares trade at a discount while the broader scorecard still leans expensive. A roughly 5x gain over five years can signal that a lot of optimism is already reflected in Eli Lilly’s share price, putting more focus on what investors are paying for that growth story today. Expectations tied to obesity,...
Viking's latest program seeks to push the envelope in weight loss efficacy.
There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.
Healthcare stocks were mixed late Friday afternoon, with the NYSE Healthcare Index unchanged and the
Novo Nordisk is finally getting one up on its biggest rival.
Omada, an Eli Lilly partner, has soared more than 118% in just a few months, moving up the right side of a new base.
Sector leader Eli Lilly is in a buy zone above a pivot at 1,133.95 ahead of second-quarter results, due on Aug. 5.
Find insight on Eli Lilly, GSK, Intuitive Surgical and more in the latest Market Talks covering the Health Care sector.
Eli Lilly's (LLY) long-term GLP-1 franchise is unlikely to face significant pressure from generic GL
LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.
Big pharma is making a big bet that a DMT nasal spray could succeed where daily Prozac pills fall short.
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by...
The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures.
Eli Lilly and Company has agreed to acquire AtaiBeckley (NasdaqGM:ATAI) in a cash and contingent value rights deal valued at up to $3.8b, putting fresh focus on the stock’s risk and return trade off. See our latest analysis for AtaiBeckley. AtaiBeckley’s share price has reacted sharply to the Eli Lilly bid, with a 33.4% 1 day share price return on the announcement and an 84.75% year to date share price return. The 1 year total shareholder return of 156.27% contrasts with a 5 year total...
Eli Lilly's first venture into psychedelic medicine, a takeover of AtaiBeckley worth up to $3.8 billion, is above all a vindication of two decades of British research once dismissed as fringe science. The prize at the centre of the deal is BPL-003, a nasal spray formulation of the psychedelic...
Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.
The deal gives Eli Lilly access to a psychedelic-based nasal spray that studies show curbs treatment-resistant depression in a single dose.
Apple, AtaiBeckley and UnitedHealth Group jumped to yearly highs as positive company catalysts, Wall Street upgrades, and strong earnings pushed shares higher.
AtaiBeckley climbed to a new four-year high on Thursday, as investors bought into its shares following news that Eli Lilly agreed to acquire the company for up to $3.8 billion. In intra-day trading, the stock surged to a record high of $7.22 before trimming gains to end the session just up by 33.40 percent at […]
The psychedelic drugmaker is being acquired.
Eli Lilly (LLY) has seen a lot of bullish calls from Wall Street in July. Guggenheim, Truist, Bank of America, Bernstein, and JPMorgan all raised their price targets in the first half of the month. Then UBSwent higher than nearly all of them. UBS's call is worth watching closely because ...
Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
